New and improved therapies to treat and protect against drug dependence and abuse are urgently needed. In the United States alone about 50 million people regularly smoke tobacco and another 5 million are addicted to other drugs. In a given year, millions of these individuals attempt with or without medical assistance to quit using drugs, though relapse remains the norm. Furthermore, each year several million teenagers start smoking and nearly as many take illicit drugs for the first time. Research is advancing on promising new means of treating drug addiction using immunotherapies and sustained-release (depot) medications. The aim of this research is to develop medications that can block or significantly attenuate the psychoactive effects of such drugs as cocaine, nicotine, heroin, phencyclidine, and methamphetamine for weeks or months at a time. This represents a fundamentally new therapeutic approach that shows promise for treating drug addiction problems that were difficult to treat in the past. Despite their potential benefits, however, several characteristics of these new methods pose distinct behavioral, ethical, legal, and social challenges that require careful scrutiny. Such issues can be considered unique aspects of safety and efficacy that are fundamentally related to the distinct nature and properties of these new types of medications.
Table of Contents
|1 Introduction and Background||7-15|
|2 Clinical Trials||16-22|
|3 Treatment, Financing, and Costs||23-36|
|4 Behavioral Responses and Consent||37-53|
|Appendix A: Vaccines and Depot Medications for Drug Addiction: Rationale, Mechanisms of Action, and Treatment Implications||61-97|
|Appendix B: What Will We Learn from the FDA Clinical Trials Process and What Will We Still Want to Know About Immunotherapies and Depot Medications to Treat Drug Dependence?||98-124|
|Appendix C: Putting Addiction Treatment Medications to Use: Lessons Learned||125-139|
|Appendix D: Adoption of Drug Abuse Treatment Technology in Speciality and Primary Care Settings||140-172|
|Appendix E: The Use of Immunotherapies and Sustained-Release Formulations in the Treatment of Drug Addiction: Will Current Law Support Coercion?||173-187|
|Appendix F: Ethical Issues in Immunotherapies and Depot Mechanisms for Substance Abuse||188-212|
|Appendix G: Costs and Benefits of Immunotherapies or Depot Medications for the Treatment of Drug Abuse||213-240|
|Appendix H: Anticipating Unintended Consequences of Vaccine-Like Immunotherapies for Addictive Drug Use||241-275|
|Appendix I: Vaccines and Immunotherapies to Control Addiction in Minors: The Legal Framework||276-299|
|Appendix J: Biographical Sketches of Committee Members and Staff||300-306|
The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:
Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:
Rightslink Customer Care
Tel (toll free): 877/622-5543
To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.
To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, please click here to view more information.